PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...

Joint injury induces rapid and sustained diversification of resident and infiltrating synovial macrophage phenotypes, underpinning osteoarthritis-associated synovitis.

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...